Monday, October 26, 2026
ExploreSearch
Via News
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Press releaseGlobeNewswire· March 26, 2026

DBV Technologies publie ses résultats financiers annuels 2025 et fait le point sur ses activités

View original at globenewswire.com
“Trésorerie et équivalents de trésorerie de 194 millions de dollars au 31 décembre 2025, auxquels s'ajoutent 94 millions de dollars de produit brut supplémentaire reçu le 16 janvier 2026”
Verbatim excerpt from the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • DBV is pleased with the progress made in strengthening capabilities and building a company ready for the launch of Viaskin Peanut

    60% confidence

  • These estimates are based on the Company's current forecasts and exclude any additional expenses related to programs other than Viaskin Peanut, or resulting from potential licensing or acquisition operations of additional product candidates or technologies

    60% confidence

  • The Company may have based these estimates on assumptions that could prove to be inaccurate, and could consequently use its resources more quickly than anticipated

    60% confidence

  • Management estimates that the Company has sufficient resources to fund operations through the second quarter of 2027

    60% confidence

  • DBV remains firmly committed to making Viaskin Peanut available to children aged 1 to 7 years allergic to peanuts

    60% confidence

  • We approached 2025 focused on strengthening the company's financial position, completing the VITESSE study, launching the COMFORT Toddlers study, and preparing for the BLA submission and potential commercial launch in the United States

    60% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com